Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world data of adolescents and young adults with acute lymphoblastic leukemia treated with a modified GMALL protocol in India: Treatment outcomes and challenges

View Full Paper
Ask AI
Bookmark
Share

Authors

UKUday KulkarniSSSushil SelvarajanGJGeetha Joseph

Discussion

Loading...

Member takes

Overview

Observational analysis highlights treatment outcomes in adolescents and young adults with acute lymphoblastic leukemia, suggesting financial constraints impact survival and adherence.

Key Points

  • A total of 75.6% achieved morphologic complete remission after using the modified GMALL protocol.
  • The estimated 5-year overall survival in this cohort is 46.0%, indicating challenges in treatment outcomes.
  • Retrospective analysis from 2015 to 2023 included 262 patients treated specifically with the modified GMALL protocol.
  • Financial constraints significantly influenced treatment adherence and discontinuations, impacting survival rates.

Cite This Study

Kulkarni et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d550https://doi.org/10.1182/blood-2025-6321
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Favorable survival and tolerability of the GMALL protocol in adolescents and young adults with ALL: A single-center experience2025
  2. 2Overall survival in patients with acute lymphoblastic leukemia in the aya population, treated with modified pediatric chemotherapeutic schemes, a real-life study2025
  3. 3Pediatric inspired (BFM) protocol in adolescent and young adults (AYA) with acute lymphoblastic leukemia (ALL) in India: Real‑world treatment timelines and impact of delays on survival2025
  4. 4T-cell acute lymphoblastic leukemia: therapeutic outcomes in adolescents and young adults2025 · 2 citations
  5. 5Effectiveness and prognostic impact of BMI, MRD and CNS involvement in AYA patients with Philadelphia-negative ALL treated using the AYA-15 protocol: Real-world from a tertiary center in the middle east2025